Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Repare Therapeutics
Biotech
Repare lays off 25% of staff as biotech halts preclinical R&D
The biotech is scaling back preclinical work to focus on more advanced candidates such as a synthetic lethal drug handed back by Roche in February.
James Waldron
Aug 29, 2024 6:36am
Canadian VC Amplitude unveils $192M biotech fund
May 29, 2024 10:30am
Roche axes Repare's oncology drug days after starting study
Feb 13, 2024 5:51am
Roche pays Repare $125M to join Big Pharma peers in cancer race
Jun 2, 2022 8:27am
After Repare IPO success, Amplitude closes CA$200M fund
Jun 17, 2021 5:00am
Forma, Repare snag nearly $500M collectively in upsized IPOs
Jun 19, 2020 10:10am
